← board
OVID
distress 4/10 · elevated risk$2.370%today-20% from 52w high
Lead: psychosis associated with Parkinson's disease and Lewy body dementia · est. market ~$6B (approx, global)
Revenue
pre-revenue
Liquidity
$115M
Runway
2.7 yrs
Shares 1y
+163%
Price & events
+35.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.4%
1D
-3.3%
1W
+2.2%
1M
-11.6%
3M
+40.2%
6M
+238.6%
1Y
+125.7%
2Y
-36.6%
5Y
-2.5%
All
Overview
- Market Cap
- $442.34M
- Volume
- 3.61M
- 52 Week Range
- $0.37 – $2.96
- Total Shares
- 186.64M
- Float Shares
- 154.02M
- Short %
- 13.59%
- % Held by Insiders
- 7.04%
- % Held by Institutions
- 63.85%
- RVOL
- 1.14x
- Beta
- 0.19
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 4
- 2026-08-12Estimated 45%earningsEarningsEarnings releaseyahoo
- Q2 2026trial initiationsecondaryPhase 1OV4071 · Initiate Phase 1/1b clinical study of OV4071SEC 8-K
- Q1 2026regulatory submissionFiled (NDA/BLA)OV4071 · Regulatory submission for Phase 1/1b trial of oral KCC2 direct activatorSEC 8-K
- 2025-06-23partnershipganaxolone · Ovid amended exclusive patent license with Immedica, sold royalty obligations for $7M, agreed to expand field and territory within six months.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-04-15WedbushOutperform
- 2026-04-09HC Wainwright & Co.Buy
- 2026-03-26BTIGBuy
- 2026-03-20WedbushOutperform
- 2025-12-22LifeSci CapitalOutperform
- 2025-12-22HC Wainwright & Co.Buy
Competitors — psychosis associated with Parkinson's disease and Lewy body dementia
- none identified
Recent news
- 2026-07-23Los Angeles County Department of Public Health and OpenEvidence Partner to Connect Physicians With Local Public Health Guidance - Business Wire
- 2026-07-21B.Riley reiterates Buy on Ovid Therapeutics stock, $5 target - Investing.com
- 2026-07-21New Lothrop Girls Varsity Basketball @ Ovid-Elsie - MaxPreps
- 2026-07-19Ovid-Elsie Boys Varsity Basketball @ Chesaning - MaxPreps
- 2026-07-18Ovid holds comprehensive plan public workshop - Finger Lakes Times
- 2026-07-18Ovid-Elsie Varsity Softball @ Birch Run - MaxPreps
- 2026-07-17Hemlock Varsity Softball @ Ovid-Elsie - MaxPreps
- 2026-07-17Montrose vs Ovid-Elsie | Football | 09/15/2023 - MaxPreps
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.